LUCY: A Study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Patients Previously Treated With Chemotherapy
Phase 2
Completed
- Conditions
- Lung CancerCancer of LungCancer of the LungNon-Small Cell Lung CarcinomaCarcinoma, Non-Small Cell Lung
- Interventions
- Registration Number
- NCT00328588
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
A study for the treatment of Non-Small Cell Lung Cancer (NSCLC) in patients previously treated with chemotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
- Histologically or cytologically confirmed non-small cell lung cancer.
- Prior chemotherapy regimen(s) for lung cancer
Exclusion Criteria
- History of other malignancy in the last 5 years
- Major surgery within the past 21 days
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 YM155 7 days continuous infusion
- Primary Outcome Measures
Name Time Method Tumor response rate (CR+PR) In first 6 cycles
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the molecular mechanism of YM155 in targeting NSCLC cell survival pathways?
How does YM155 compare to standard-of-care therapies in previously treated NSCLC patients?
Which biomarkers correlate with YM155 response in phase 2 NSCLC trials?
What are the adverse event profiles and management strategies for YM155 in NSCLC?
Are there combination therapies with YM155 showing enhanced efficacy in NSCLC treatment?